SDCBP: A Potential New Treatment for High Blood Pressure and Cancer

Target Name: SDCBP

NCBI ID: G6386

SDCBP

SDCBP: A Potential New Treatment for High Blood Pressure and Cancer

SDCBP (steroid-conjugated penapril) is a drug that is currently being studied for its potential as a treatment for various diseases, including heart failure, hypertension, and diabetes. It is a combination of two different drugs, indomethacin and terlipressin, which work together to treat these conditions.

One of the unique features of SDCBP is its ability to target the PDGF receptor, which is a protein that is found on the surface of many different types of cells in the body. This receptor is involved in many different processes in the body, including cell growth, differentiation, and angiogenesis (the formation of new blood vessels).

PDGF receptor is a protein that is involved in many different processes in the body, including cell growth, differentiation, and angiogenesis.

SDCBP works by blocking the angiotensin II receptor, which can help to reduce the production of angiotensin II, a hormone that causes blood vessels to constrict and raise blood pressure. This can help to improve blood flow and reduce the risk of heart failure, hypertension, and other conditions that are associated with high blood pressure.

In addition to its potential use in treating hypertension and heart failure, SDCBP may also be a useful biomarker for some types of cancer. Studies have shown that the levels of SDCBP in the blood can be elevated in people with certain types of cancer, such as breast cancer and lung cancer. This may be an indication that SDCBP can be used as a diagnostic tool for these types of cancer.

Another potential use for SDCBP is in treating some types of diabetes. Studies have shown that SDCBP can help to lower the levels of blood glucose in people with diabetes, which can help to improve the symptoms of this condition.

Overall, SDCBP is a drug that is still in the early stages of development, but it has the potential to be a valuable new treatment for a variety of conditions. Further studies are needed to fully understand its potential and to determine its safety and effectiveness.

Protein Name: Syndecan Binding Protein

Functions: Multifunctional adapter protein involved in diverse array of functions including trafficking of transmembrane proteins, neuro and immunomodulation, exosome biogenesis, and tumorigenesis (PubMed:26291527). Positively regulates TGFB1-mediated SMAD2/3 activation and TGFB1-induced epithelial-to-mesenchymal transition (EMT) and cell migration in various cell types. May increase TGFB1 signaling by enhancing cell-surface expression of TGFR1 by preventing the interaction between TGFR1 and CAV1 and subsequent CAV1-dependent internalization and degradation of TGFR1 (PubMed:25893292). In concert with SDC1/4 and PDCD6IP, regulates exosome biogenesis (PubMed:22660413). Regulates migration, growth, proliferation, and cell cycle progression in a variety of cancer types (PubMed:26539120). In adherens junctions may function to couple syndecans to cytoskeletal proteins or signaling components. Seems to couple transcription factor SOX4 to the IL-5 receptor (IL5RA) (PubMed:11498591). May also play a role in vesicular trafficking (PubMed:11179419). Seems to be required for the targeting of TGFA to the cell surface in the early secretory pathway (PubMed:10230395)

The "SDCBP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDCBP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets